In this situation, disruption of EphB4-EphrinB2 interaction may represent a potential opportunity for anti-angiogenic cancer therapy, and on the other hand, a more efficient vasculature due to increased EphrinB2 signaling may at least facilitate delivery of anticancer drugs to tumor tissue [42,43]. Here, EPHB4 is linked to cancer.